R&D channel feed

Lit­tle Mar­i­nus sees its shares eclipsed as the Sage ri­val fails to com­pare on PPD in PhII

6 years ago

3 years af­ter the FDA forced Chi­as­ma back in­to PhI­II, they’re back with pos­i­tive da­ta — but now they have a ri­val

6 years ago

Aca­dia is mak­ing the best of it, but their lat­est PhI­II Nu­plazid study is a bust

6 years ago
Pharma

Take­da re­ports sec­ond PhI­II win for sub­cu­ta­neous En­tyvio as reg­u­la­tors re­view ex­pand­ed use

6 years ago
Pharma

Some Big Phar­mas stepped up their game on da­ta trans­paren­cy — but which flunked the test?

6 years ago
FDA+

Break­ing the death spi­ral: Hal Bar­ron talks about trans­form­ing the mori­bund R&D cul­ture at GSK in a crit­i­cal year for the late-stage pipeline

6 years ago
People

In­tec blitzed by PhI­II flop as lead pro­gram fails to beat Mer­ck­'s stan­dard com­bo for Parkin­son’s

6 years ago

In an­oth­er dis­ap­point­ment for in­vestors, FDA slaps down Bio­haven’s re­vised ver­sion of an old ALS drug

6 years ago

MyoKar­dia re­claims US roy­al­ty rights to heart drugs, com­plet­ing con­scious un­cou­pling from Sanofi

6 years ago

On a hot streak, No­var­tis ex­ecs run the odds on their two most im­por­tant PhI­II read­outs. Which is 0.01% more like­ly to suc­ceed?

6 years ago

Pre­ci­sion Bio­Sciences backs off-the-shelf can­cer cell ther­a­py ef­fort with new man­u­fac­tur­ing plant

6 years ago

Af­ter a decade, Vi­iV CSO John Pot­tage says it's time to step down — and he's hand­ing the job to long­time col­league Kim Smith

6 years ago
People

As Ac­thar trou­bles per­sist, Mallinck­rodt in­vests in RNAi and Si­lence Ther­a­peu­tics

6 years ago

Go­ing in­side cells, Sung Joo Lee has sketched some big goals for his small — but glob­al — team of drug hunters

6 years ago
Startups

Mallinck­rodt forced to shut­ter ALS study test­ing its con­tro­ver­sial Ac­thar gel

6 years ago

As ri­vals march on, No­var­tis se­cures pri­or­i­ty FDA re­view for sick­le cell dis­ease ther­a­py

6 years ago
FDA+

Mi­cro­cap Capri­cor soars on in­ter­im PhII DMD da­ta show­ing func­tion­al ben­e­fit for old­er pa­tients

6 years ago
Cell/Gene Tx

Eton Phar­ma hand­ed CRL for re­for­mu­lat­ed con­junc­tivi­tis eye drop

6 years ago
FDA+

FDA bats back As­traZeneca's SGLT di­a­betes drug for Type 1 di­a­betes — block­ing a class on safe­ty fears

6 years ago

Hal Bar­ron's team at GSK scores a win with pos­i­tive Ze­ju­la PhI­II front­line study — now comes the hard part

6 years ago

Gilead un­leash­es a $5B late-stage cash al­liance with Gala­pa­gos — lay­ing out O'­Day's R&D strat­e­gy

6 years ago
Deals
Pharma

Broad star Feng Zhang un­veils a new CRISPR plat­form, edit­ing RNA and elim­i­nat­ing Alzheimer's threat — in cells

6 years ago

Am­gen, No­var­tis scrap Alzheimer's stud­ies — is BACE fi­nal­ly dead or will Bio­gen and Ei­sai car­ry on?

6 years ago

Scripps-led con­sor­tium scores $129M NIH grant to work on vac­cine for stub­born HIV

6 years ago
First page Previous page 238239240241242243244 Next page Last page
A service from the Financial Times